Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.

Takabe M, Matsuda T, Hirota Y, Hashimoto N, Nakamura T, Sakaguchi K, Ogawa W, Seino S.

Diabetes Res Clin Pract. 2012 Dec;98(3):e32-5. doi: 10.1016/j.diabres.2012.09.036.

PMID:
23068961
2.

The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.

Moon HS, Kim MK, Son MH.

Arch Pharm Res. 2011 Jul;34(7):1041-3. doi: 10.1007/s12272-011-0721-z. Review.

PMID:
21811909
4.
5.

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.

Vilsbøll T, Brock B, Perrild H, Levin K, Lervang HH, Kølendorf K, Krarup T, Schmitz O, Zdravkovic M, Le-Thi T, Madsbad S.

Diabet Med. 2008 Feb;25(2):152-6. doi: 10.1111/j.1464-5491.2007.02333.x.

PMID:
18201212
6.

Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.

Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O.

Diabetes Care. 2007 Aug;30(8):2032-3. No abstract available.

PMID:
17468345
7.

Liraglutide in the management of type 2 diabetes.

Wajcberg E, Amarah A.

Drug Des Devel Ther. 2010 Oct 22;4:279-90. doi: 10.2147/DDDT.S10180. Review.

8.

Next-generation GLP-1 therapy: an introduction to liraglutide.

Repas T.

Postgrad Med. 2011 Sep;123(5):239-47. doi: 10.3810/pgm.2011.09.2480. Review.

PMID:
21904107
9.

Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.

Schwasinger-Schmidt T, Robbins DC, Williams SJ, Novikova L, Stehno-Bittel L.

Pharmacol Res. 2013 Oct;76:58-66. doi: 10.1016/j.phrs.2013.07.005.

10.

C-peptide response to glucagon in type 2 diabetes mellitus: a comparison with oral glucose tolerance test.

Iwasaki Y, Kondo K, Hasegawa H, Oiso Y.

Diabetes Res. 1994;25(3):129-37.

PMID:
7671552
12.
13.
14.
15.

Incretins: a new treatment option for type 2 diabetes?

Geelhoed-Duijvestijn PH.

Neth J Med. 2007 Feb;65(2):60-4. Review.

16.

Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial.

Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B.

Diabetes Care. 2014 Dec;37(12):3270-8. doi: 10.2337/dc14-0893.

PMID:
25249651
17.

Independent measures of insulin secretion and insulin sensitivity during the same test: the glucagon-insulin tolerance test.

Dorkhan M, Tripathy D, Malm G, Asgharian H, Tuomi T, Groop L.

J Intern Med. 2008 Jul;264(1):62-71. doi: 10.1111/j.1365-2796.2008.01921.x.

18.

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.

Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T, Shimomura I.

Cardiovasc Diabetol. 2011 Dec 1;10:109. doi: 10.1186/1475-2840-10-109.

19.

Efficacy of liraglutide as a follow-up therapy after resolution of glucotoxicity with intensive insulin therapy.

Arakawa M, Ebato C.

Diabetes Metab Syndr. 2013 Oct-Dec;7(4):223-5. doi: 10.1016/j.dsx.2013.10.002.

PMID:
24290089
20.

Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.

Yoshida M, Asai M, Miyata M, Ogawa K, Maeda H, Oiso Y.

Diabetes Res Clin Pract. 2012 Jun;96(3):e55-6. doi: 10.1016/j.diabres.2011.12.024. No abstract available.

PMID:
22257418
Items per page

Supplemental Content

Support Center